Ex-EU drug watchdog head's consulting gig scrutinized

The European Medicines Agency has received some fresh requests to investigate former head Thomas Lonngren, who is now an industry consultant, for potential conflicts of interest committed before he left the agency late last year. Although the EMA has already consented to Lonngren's role as a consultant to drug companies, advocacy groups believe he bent some ethics rules when he arranged for the position while still working for the agency. They want the agency to take another look into the matter, Pharmalot reported. Article

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.